CENTER FOR DRUG EVALUATION AND RESEARCH

APPROVAL PACKAGE FOR:

APPLICATION NUMBER
21-146

Approval Letter

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville MD 20857

NDA 21-146

JUL 9 2001

Abbott Laboratories
Attention: Mr. Jonathan P. Dohnalek
Manager, Regulatory Affairs
Hospital Products Division
D-389, Bldg AP30
200 Abbott Park Road
Abbott Park, IL 60064-6157

Dear Mr. Dohnalek:

Please refer to your new drug application (NDA) dated December 16, 1999, received December 21, 1999, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Atropine Sulfate Injection, USP 0.1mg/mL (5 and 10 mL) and 0.05 mg/mL (5 mL).

We acknowledge receipt of your submission dated March 30, 2001. Your submission of March 30, 2001 constituted a complete response to our December 19, 2000 action letter.

This new drug application provides for the use of Atropine Sulfate Injection, USP 0.1mg/mL (5 and 10 mL) and 0.05 mg/mL (5 mL) for when excessive (or sometimes normal) muscarinic effects are judged to be life threatening or are producing symptoms severe enough to call for temporary, reversible muscarinic blockade.

We have completed the review of this application, as amended, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the submitted final printed labeling (package insert and immediate container and carton labels submitted March 30, 2001). Accordingly, the application is approved effective on the date of this letter.

Validation of the regulatory methods has not been completed. At the present time, it is the policy of the Center not to withhold approval because the methods are being validated. Nevertheless, we expect your continued cooperation to resolve any problems that may be identified.

As noted in our December 19, 2000 action letter, we are waiving the Pediatric Rule requirement under 21 CFR 314.55(c)(1). In addition, we are granting your request for a waiver of the bioavailability test requirements under 21 CFR 320.22(b)(1).

In addition, please submit three copies of the introductory promotional materials that you propose to use for this product. All proposed materials should be submitted in draft or mock-up form, not final print. Please submit one copy to this Division and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-42
Food and Drug Administration
5600 Fishers Lane
Rockville, Maryland 20857

Please submit one market package of the drug product when it is available.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, please contact

Mr. John Guzman
Regulatory Health Project Manager
(301) 594-5312.

Sincerely,

{See appended electronic signature page}

Raymond J. Lipicky, M.D.
Director
Division of Cardio-Renal Drug Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

CENTER FOR DRUG EVALUATION AND RESEARCH

APPROVAL PACKAGE FOR:

APPLICATION NUMBER
21-146

Approvable Letter

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville MD 20857

NDA 21-146

12/19/00

Abbott Laboratories
Attention: Jessie Y. Lee, PhD
200 Abbott Park Road D-389, AP30
Abbott Park, IL 60064-6157

Dear Dr. Lee:

Please refer to your new drug application (NDA) dated December 16, 1999, received December 21, 1999, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Atropine Sulfate Injection 0.1 mg/mL (5 and 10 mL) and 0.05 mg/mL (5 mL).

We acknowledge the receipt of your submissions dated January 13 and 14, March 24, April 4 and 6, May 12, July 17 and 21, August 28, September 29, and October 13, 2000.

We have completed the review of this application, as amended, and it is approvable. Before this application may be approved, it will be necessary for you to submit revised final printed labeling for the drug. Please note the following changes that must be made:

- The enclosed draft labeling is an initial draft and outline of concept. The DOSAGE AND ADMINISTRATION section needs your input. Note that there are no specifics included in this section, but that it contains only ranges and guides. The pediatric dosing is very difficult to extrapolate from your submission, nonetheless instructions should be included in the labeling. In your response, please identify the location in your application of the information that leads to your choices. We recommend that you contact the Division to arrange a teleconference prior to re-writing the DOSAGE AND ADMINISTRATION section.
- Please change the storage statement on the carton/container labels to be consistent with that of the package insert.

If additional information relating to the safety or effectiveness of this drug becomes available, revision of the labeling may be required.

Please note that we are waiving the Pediatric Rule requirement under 21 CFR 314.55(c)(1). In addition, we are granting your request for a waiver of the bioavailability test requirements under 21 CFR 320.22(b)(1).

In addition, please submit three copies of the introductory promotional materials that you propose to use for this product. All proposed materials should be submitted in draft or mock-up form, not final print. Please submit one copy to this Division and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-42
Food and Drug Administration
5600 Fishers Lane
Rockville, Maryland 20857

Within 10 days after the date of this letter, you are required to amend the application, notify us of your intent to file an amendment, or follow one of your other options under 21 CFR 314.110. In the absence of any such action FDA may proceed to withdraw the application. Any amendment should respond to all the deficiencies listed. We will not process a partial reply as a major amendment nor will the review clock be reactivated until all deficiencies have been addressed.

The drug product may not be legally marketed until you have been notified in writing that the application is approved.

If you have any questions, please contact

John Guzman
Regulatory Health Project Manager
(301) 594-5312.

Sincerely yours,

/S/

Raymond J. Lipicky, M.D.
Director
Division of Cardio-Renal Drug Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

Enclosure

10 pages redacted from this section of the approval package consisted of draft labeling

(pp. 2-12)